Arkolith/Insider Trading/IGC/Form 4

Prins Richard K

DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Jun 27, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
2 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 31, 2023Option exercise(M)58K—$0913K
Mar 31, 2023Option exercise(M)100K—$0855K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 20, 2023Grant(A)285K—$01.3M
Jun 20, 2023Grant(A)300K—$01.1M
Mar 31, 2023Option exercise(M)58K—$0117K
Mar 31, 2023Option exercise(M)100K—$0100K
May 25, 2022Grant(A)175K—$0175K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-23-000666) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML